Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbiotic-Lung-01
2025-523461-17-01Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of PF-08634404 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Overall survival and Progression-free survival by BICR. Planned start Jun 2026; status: authorised.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523461-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523461-17-01.